What we do GlaxoSmithKline Pharmaceuticals Ltd is a leading Indian pharmaceutical company engaged in manufacturing and distributing general medicines, vaccines, and specialty drugs across multiple therapeutic areas. |
Founded in 1,924 |
Market share Ranks among the top pharmaceutical companies in India with strong market positions in vaccines, anti-infectives, respiratory and specialty medicines. |
Problem solved Provides treatments and preventive vaccines addressing infectious diseases, chronic conditions like diabetes, oncology, respiratory and dermatological disorders. |
Top clients or who we serve Serves hospitals, clinics, healthcare providers, and patients across India; operates in B2B and B2C segments with key doctors, hospitals as customers. |
Key management Bhushan Akshikar (Managing Director), Juby Chandy (Chief Financial Officer) with significant leadership experience in pharma and global markets. |
Our journey and innovations Founded in 1924, transitioned through various name changes, expanded vaccine production since 1956, launched multiple innovative drugs and vaccines, integrated Novartis vaccine business in 2015. |
Where we operate Primarily India with manufacturing units in Nashik, Thane, and clinical development in Bangalore; exports to foreign countries present. |
Top products or what we offer Key products include Augmentin, Calpol, Eltroxin, specialty drugs in oncology and respiratory, plus vaccines like Shingrix, Priorix-Tetra, Fluarix Tetra. |
Top brands Augmentin (#1 anti-infective), Calpol (trusted pain relief), Eltroxin (thyroid therapy), Shingrix (adult vaccination), Infanrix Hexa (pediatric vaccine). |
Raw materials needed Active pharmaceutical ingredients, excipients, biological components for vaccines and formulations sourced globally and locally. |
Raw materials supplier Not specifically disclosed; procured from certified pharmaceutical raw material suppliers and contract manufacturers. |
Recurring vs cyclical contribution Revenue largely recurring from pharmaceuticals sales and vaccines with periodic innovation-driven increases. |
Our industry position Among India's leading pharmaceutical players with steady revenue growth, strong brand portfolio and expanding specialty segments. |
Financial highlights FY2025 revenue Rs 3749 crore, net profit Rs 928 crore, EBITDA margin 34.4%, steady profitable growth and improving margins. |
Geographical revenue split India contributes approximately 99% of revenues; foreign operations account for around 1%. |
Order book - |
Whats driving growth Innovation in oncology and specialty drugs, vaccines expansion, digital initiatives, and targeted therapies drive growth. |
Our future plans Focus on oncology portfolio expansion, adult immunization, digital engagement, and new product launches with ongoing infrastructure upgrades. |
Our green promise Committed to sustainability, ESG practices aligned with GSK global standards; initiatives in energy conservation and responsible manufacturing. |
Our people and values Diverse workforce with continuous development, emphasis on ethics, innovation, and customer-centric culture. |
Key challenges ahead Competitive pricing pressures, regulatory compliance, supply chain challenges, and evolving healthcare policies. |
Interesting facts One of India's oldest pharma companies, pioneer in vaccine manufacturing since 1956, strong heritage of innovation and trusted by millions globally. |
Risks and strategy Risks include market competition and regulatory changes; mitigation through innovation, portfolio diversification, and operational excellence. |
